Obesity mediated the association of exposure to polycyclic aromatic hydrocarbon with risk of cardiovascular events.
Obesity mediated the association of exposure to polycyclic aromatic hydrocarbon with risk of cardiovascular events.
复制标题
DOI：
10.1016/j.scitotenv.2017.10.238
复制
发表时间：
2018-03
期刊：
影响因子：
--
通讯作者：
Wenjun Yin;Jian Hou;T. Xu;Juan Cheng;Pei Li;Lin Wang;Youjian Zhang;Xian Wang;Chen Hu
中科院分区：
文献类型：
--
作者：
Wenjun Yin;Jian Hou;T. Xu;Juan Cheng;Pei Li;Lin Wang;Youjian Zhang;Xian Wang;Chen Hu
暴露于多环芳烃（PAHs）可导致高血压（BP）和动脉粥样硬化性心血管疾病（ASCVD）的风险增加。然而，它们之间关系的机制尚不清楚。我们调查了肥胖对暴露于多环芳烃与高血压和ASCVD风险增加之间的潜在中介作用。在重复测量研究中，对武汉市106名社区居民进行了冬夏两季的健康体检，测定了8种多环芳烃代谢产物的尿中浓度。使用线性混合效应模型或广义估计方程模型评估尿多环芳烃与高血压和ASCVD风险增加的关系。中介分析进行评估肥胖的中介作用的关联尿多环芳烃代谢物与高血压或ASCVD的风险增加。尿中多环芳烃代谢产物与血压及高血压的比值比呈正相关（均P < 0.05）。此外，尿中4-羟基菲或PAH代谢产物的浓度每增加1个单位，估计的10年ASCVD风险分别增加12.63%或11.91%（P < 0.05）。腰高比介导了29.0%的尿4-羟基菲与ASCVD风险增加的相关性（P< 0.05）。研究结果表明，多环芳烃暴露可能与血压升高和ASCVD风险增加有关。肥胖可能部分介导多环芳烃暴露与高血压或ASCVD风险增加之间的关联。
Exposure to polycyclic aromatic hydrocarbons (PAHs) could cause high blood pressure (BP) and increased risk for atherosclerotic cardiovascular disease (ASCVD). However, the mechanisms underlying the relationship between them were unclear. We investigated potential mediation effect of obesity on the association of exposure to PAHs with high BP and increased risk for ASCVD. In the repeated measures study, 106 community-dwelling residents in Wuhan, China finished the physical examination in the winter and summer seasons, eight urinary PAHs metabolites were measured. Associations of urinary PAHs with high BP and increased risk for ASCVD were assessed using either linear mixed effect models or generalized estimating equations models. Mediation analysis was performed to evaluate the mediating effect of obesity on the association of urinary PAHs metabolites with high BP or increased risk of ASCVD. We observed the positive association between urinary PAHs metabolites and BP or the odds ratios for high BP (allP< 0.05). Additionally, each one-unit increase in ln-transformed urinary levels of 4-hydroxyphenanthrene or the total of PAH metabolites was associated with a 12.63% or 11.91% increase in the estimated 10-year ASCVD risk (bothP< 0.05). The waist-to-height ratio mediated 29.0% of the association of urinary 4-hydroxyphenanthrene with increased risk of ASCVD (P< 0.05). The findings suggest that PAHs exposure may be associated with elevated BP and an increased risk of ASCVD. Obesity may partially mediate the association between PAHs exposure and higher BP or increased risk of ASCVD.